AimedBio

AIMEDBIO is a spin-off company from Samsung Medical Center (SMC), specializing in the clinical development of brain diseases. Focused on developing innovative brain disease drugs centered around antibodies, AIMEDBIO aims to provide therapeutic solutions for patients with severe brain diseases, including neuro-oncology and degenerative conditions, to save lives and improve the quality of life for patients. With a robust global network of key opinion leaders in the field, an outstanding research team with profound achievements, and a strong R&D pipeline featuring an excellent drug development platform, AIMEDBIO is an emerging leader in innovative brain disease treatments.